Rastilav Bahleda
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, CAR-T cell therapy research, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors(2014)203 cited
- → Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)(2014)173 cited
- → Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors(2014)170 cited
- → Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer(2019)166 cited
- → First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors(2012)151 cited
- → Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation(2018)141 cited
- → Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy(2013)101 cited
- → Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells(2020)94 cited
- → TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma(2016)92 cited
- → Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression(2018)64 cited